Affinage

ANXA7

Annexin A7 · UniProt P20073

Length
488 aa
Mass
52.7 kDa
Annotated
2026-06-09
31 papers in source corpus 23 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANXA7 is a Ca2+-activated GTPase and calcium/phospholipid-binding protein that couples membrane dynamics to Ca2+ signaling and acts as a tumor suppressor whose loss drives genomic instability and tumorigenesis (PMID:10570150, PMID:11287641, PMID:14608035). Its membrane fusion, calcium binding, and phospholipid binding activities depend on the GX(X)GT endonexin-fold repeats, and disrupting these by mutagenesis abolishes fusion with artificial membranes and lowers IP3 receptor expression (PMID:37240163). At the organismal level, ANXA7 is required for IP3 receptor expression and IP3-dependent Ca2+ signaling that supports regulated secretion: heterozygous knockout mice have profoundly reduced islet IP3R and defective glucose-induced insulin secretion, with altered downstream responses to muscarinic and ryanodine-receptor agonists rather than direct changes to Ca2+ stores (PMID:10570150, PMID:22613970). The GTPase activity is a regulatory switch exploited pharmacologically: its activation promotes AMPK phosphorylation with consequent suppression of mTORC1 and STAT3 signaling and prostate cancer metastasis (PMID:29247827), drives autophagy through the mTOR/TFEB axis (PMID:37620352), and governs apoptotic and oxidative-stress programs (PMID:31408583, PMID:39996504). ANXA7 tumor suppression operates through control of cell-cycle and survival outputs—abolishing oncogenic LMW-cyclin E, preserving FOXO3A, and inhibiting Cyclin B1—and through partner interactions including a BART complex that restrains PKCα-driven invasion, CDC5L in myeloma, and the ZBTB16 axis controlled epigenetically by UHRF1/DNMT1 (PMID:22532868, PMID:32526706, PMID:39308302). Its abundance is set both transcriptionally, by a multi-hnRNP repressor complex at a steroid-responsive promoter element in androgen-resistant prostate cells (PMID:20190808), and post-translationally, via RNF168-mediated ubiquitination and degradation, the loss of which suppresses autophagy and promotes NLRP3-inflammasome pyroptosis in Crohn's disease (PMID:41518435). ANXA7 also acts in damaged-mitochondria turnover by interacting with BASP1 in Parkin-dependent mitophagy (PMID:31975592) and as an adaptor linking TIA1 ribonucleoprotein granules to cytoplasmic dynein for axonal transport [PMID:bio_10.1101_2025.01.16.633295].

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1999 High

    Established ANXA7 as a Ca2+-activated GTPase functionally required for IP3 receptor-dependent Ca2+ signaling and regulated secretion in vivo, answering whether the protein had an essential physiological role.

    Evidence anx7-/- and anx7+/- knockout mice with electrophysiology, Ca2+ imaging, and insulin secretion assays

    PMID:10570150

    Open questions at the time
    • Mechanism by which ANXA7 controls IP3R expression not defined
    • Cause of embryonic cerebral hemorrhage in nulls not resolved
  2. 2001 Medium

    Defined ANXA7 as a tumor suppressor by showing wild-type re-expression suppresses prostate tumor cell growth and that the locus undergoes loss of heterozygosity in primary tumors.

    Evidence wt-ANX7 transfection, colony formation assays, LOH analysis at 10q21, and tissue microarray IHC

    PMID:11287641

    Open questions at the time
    • Molecular targets of growth suppression not yet identified
    • Single-lab functional overexpression
  3. 2003 Medium

    Showed that Anx7 haploinsufficiency causes genomic instability and spontaneous tumorigenesis, linking dosage to a broad transcriptional program of tumor suppressor, DNA repair, and apoptosis genes.

    Evidence Anx7(+/-) mouse with genome expression arrays, spectral karyotyping, and laser-capture microdissection

    PMID:14608035

    Open questions at the time
    • Direct molecular driver of instability not identified
    • Correlative array data
  4. 2002 Medium

    Extended the IP3R-dependent secretory phenotype to adrenal chromaffin cells, showing ANXA7 loss disrupts nutritional-state sensing and causes gland hyperplasia.

    Evidence Anx7(+/-) mouse cDNA microarray and adrenal histological phenotyping

    PMID:12438089

    Open questions at the time
    • Link between IP3R loss and gene dysregulation not mechanistically resolved
  5. 2010 Medium

    Identified a transcriptional repression mechanism, showing a multi-hnRNP complex binds a steroid-responsive promoter element to aberrantly control ANXA7 in androgen-resistant cancer cells.

    Evidence promoter mapping, EMSA, MALDI-TOF identification of hnRNPs, and antibody interference in PC3 vs PrEC cells

    PMID:20190808

    Open questions at the time
    • Functional consequence on tumor phenotype not directly tested
    • Single-lab
  6. 2012 Medium

    Connected ANXA7 to invasion control by showing the BART-ANX7 complex restrains PKCα activity in pancreatic cancer.

    Evidence Co-IP, reciprocal knockdown, PKCα activity and invasion assays with PKCα inhibitors

    PMID:22532868

    Open questions at the time
    • Structural basis of BART-ANX7 binding unknown
    • Single Co-IP for interaction
  7. 2012 Medium

    Refined the secretory phenotype by demonstrating that Anx7 haploinsufficiency alters IP3R/RyR downstream signaling rather than Ca2+ stores themselves.

    Evidence Anx7(+/-) beta-cell electrophysiology, Ca2+ imaging, and pharmacological agonists

    PMID:22613970

    Open questions at the time
    • Molecular link between ANXA7 and receptor signaling not pinpointed
  8. 2017 Medium

    Established the GTPase activity as a druggable anti-metastatic switch acting through AMPK/mTORC1/STAT3, and identified RKIP as a negative regulator of its activation.

    Evidence small-molecule SEC GTPase activation, pathway Western blots, RKIP-ANXA7 interaction, orthotopic metastasis model

    PMID:29247827

    Open questions at the time
    • Direct GTPase substrate/effector coupling to AMPK undefined
  9. 2016 Medium

    Demonstrated GTPase activity controls a TGFB2-OT1/LARP1/HMBOX1 translational axis in endothelial cells, with ANXA7 dependency confirmed by knockdown rescue.

    Evidence ABO GTPase inhibition, ANXA7 KD rescue, HMBOX1 quantification, apoE-/- mouse model

    PMID:27506770

    Open questions at the time
    • How GTPase state controls lncRNA expression not resolved
  10. 2019 Medium

    Revealed a nuclear function: GTPase inhibition drives ANXA7 nuclear translocation and interaction with XRN2 to regulate read-through transcription and endothelial apoptosis.

    Evidence ABO inhibition, lncRNA microarray, ANXA7-XRN2 Co-IP, nuclear imaging, TIA1 processing assay

    PMID:31408583

    Open questions at the time
    • Mechanism of nuclear import not defined
    • Single Co-IP for XRN2 interaction
  11. 2019 Medium

    Showed ANXA7 promotes trophoblast survival and proliferation through JAK1/STAT3 and BCL2, broadening its survival-signaling role beyond cancer.

    Evidence siRNA KD and overexpression in HTR-8/SVneo cells with apoptosis and proliferation readouts

    PMID:31446642

    Open questions at the time
    • Direct ANXA7 effector linking to JAK1/STAT3 unknown
  12. 2020 Medium

    Identified ANXA7 recruitment to damaged mitochondria and a role in Parkin-dependent mitophagy via BASP1 interaction.

    Evidence DIA mitochondrial proteomics, translocation assay, ANXA7-BASP1 Co-IP, CCCP treatment

    PMID:31975592

    Open questions at the time
    • Functional consequence of BASP1 binding for mitophagy flux not quantified
  13. 2020 Medium

    Showed a context-dependent oncogenic role in myeloma, with ANXA7 binding CDC5L to drive proliferation and adhesion-mediated drug resistance.

    Evidence bidirectional manipulation in U266/RPMI8226 cells, ANXA7-CDC5L Co-IP, BMSC co-culture

    PMID:32526706

    Open questions at the time
    • Reconciliation with tumor suppressor role in other tissues unaddressed
  14. 2021 Low

    Reported LEPR-ANXA7 interaction regulating ERK1/2 and JAK2/STAT3 in hepatocellular carcinoma metastasis.

    Evidence LEPR-ANXA7 Co-IP with pathway Western blots and LEPR manipulation

    PMID:33397392

    Open questions at the time
    • Single Co-IP without reciprocal validation
    • ANXA7-specific mechanistic depth limited
  15. 2023 Medium

    Mapped a neuroprotective axis where activated ANXA7 GTPase interacts with LAMP5 (via Asp411) to drive mTOR/TFEB autophagy and limit neuronal apoptosis after injury.

    Evidence ANXA7-LAMP5 Co-IP, Asp411 mutagenesis, GTPase activation, SCI mouse rescue with CatWalk

    PMID:37620352

    Open questions at the time
    • Direct GTPase-LAMP5 coupling mechanism not fully resolved
  16. 2023 Medium

    Provided structure-function evidence that the GX(X)GT endonexin-fold repeats mediate membrane fusion, Ca2+/phospholipid binding, and IP3R/PI3K-AKT-mTOR control.

    Evidence triple-mutant mutagenesis, artificial membrane fusion and binding assays, pathway Western blots in prostate cancer cells

    PMID:37240163

    Open questions at the time
    • No high-resolution structure of the active GTPase
    • Single-lab in vitro reconstitution
  17. 2024 Medium

    Defined an epigenetic control circuit in breast cancer where UHRF1/DNMT1-mediated ZBTB16 silencing reduces ANXA7, derepressing Cyclin B1 and enabling proliferation.

    Evidence ZBTB16-ANXA7 Co-IP, methylation-specific PCR, ChIP, rescue experiments, xenograft

    PMID:39308302

    Open questions at the time
    • Whether ZBTB16 binding affects ANXA7 GTPase activity not tested
  18. 2025 Medium

    Linked ANXA7 GTPase activation to lipid metabolism and antioxidant defense via PPARγ stabilization, Perilipin 5, and NRF2/GPX4 in injured neurons.

    Evidence GTPase activation, ANXA7-PPARγ Co-IP, lipid droplet/mitochondria imaging, SCI mouse model

    PMID:39996504

    Open questions at the time
    • Direct mechanism of PPARγ stabilization undefined
  19. 2026 Medium

    Identified post-translational control of ANXA7 by RNF168-mediated ubiquitination, with loss promoting NLRP3-inflammasome pyroptosis in Crohn's disease.

    Evidence RNF168-ANXA7 Co-IP/MS, ubiquitination assay, IL-10 KO and conditional RNF168 mouse models, organoids

    PMID:41518435

    Open questions at the time
    • Ubiquitination site on ANXA7 not mapped
    • ELK1-RNF168 regulation correlative
  20. 2025 Medium

    Defined ANXA7 as a dynein adaptor for axonal TIA1 RNP transport, with elevated Ca2+ disrupting the linkage and causing pathological aggregation.

    Evidence live axonal RNP imaging, ANXA7-TIA1-dynein Co-IP, Ca2+ manipulation, axonopathy models (preprint)

    PMID:bio_10.1101_2025.01.16.633295

    Open questions at the time
    • Not yet peer-reviewed
    • Binding interfaces with dynein/TIA1 not mapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single Ca2+-activated GTPase reconciles tumor-suppressive and context-dependent oncogenic roles, and how GTP hydrolysis is mechanistically coupled to its many effector pathways, remains unresolved.
  • No structure of the active GTPase or GTP-bound effector complex
  • Switch between tumor suppressor and oncogenic outputs unexplained
  • Direct enzymatic substrate of the GTPase activity unidentified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003924 GTPase activity 5 GO:0008289 lipid binding 2 GO:0098772 molecular function regulator activity 2 GO:0060090 molecular adaptor activity 1
Localization
GO:0005634 nucleus 1 GO:0005739 mitochondrion 1 GO:0005811 lipid droplet 1 GO:0005886 plasma membrane 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 3 R-HSA-1643685 Disease 3 R-HSA-5357801 Programmed Cell Death 3 R-HSA-9612973 Autophagy 3
Partners
BARTBASP1CDC5LLAMP5PPARGTIA1XRN2ZBTB16

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 ANX7/ANXA7 encodes a Ca2+-activated GTPase that supports Ca2+/GTP-dependent secretion events and Ca2+ channel activities; the homozygous knockout (anx7-/-) is embryonically lethal at E10 due to cerebral hemorrhage, while heterozygous anx7(+/-) mice show defective insulin secretion linked to profound reduction in IP3 receptor expression and function in pancreatic islets. Gene knockout mouse model (anx7-/- and anx7+/-), electrophysiology, electrooptical Ca2+ recordings, insulin secretion assays Proceedings of the National Academy of Sciences of the United States of America High 10570150
2001 Wild-type ANX7 transfection markedly reduces human prostate tumor cell proliferation and colony formation in LNCaP and DU145 cell lines, demonstrating tumor suppressor activity; loss of heterozygosity at the ANX7 locus (10q21) is found in 35% of primary prostate tumors. Transfection of wild-type ANX7 into prostate tumor cell lines, colony formation assay, loss-of-heterozygosity analysis with microsatellite markers, tissue microarray immunohistochemistry Proceedings of the National Academy of Sciences of the United States of America Medium 11287641
2003 Haploinsufficiency of Anx7 in the Anx7(+/-) mouse drives genomic instability, reduction of multiple tumor suppressor genes, DNA repair genes, and apoptosis-related genes, and promotes spontaneous tumorigenesis (23% incidence) with chromosomal aberrations. Anx7(+/-) knockout mouse; genome array expression profiling; spectral karyotyping; in situ analysis by tissue imprinting; laser-capture microdissection Proceedings of the National Academy of Sciences of the United States of America Medium 14608035
2002 In Anx7(+/-) knockout mice, chromaffin cells of the adrenal gland show defective IP3 receptor expression and an inability to discriminate nutritional state (fed vs. fasted), resulting in sustained expression of nutritionally sensitive genes (chromogranin A/B, DβH) and adrenal gland hypertrophy/chromaffin cell hyperplasia. Anx7(+/-) knockout mouse; cDNA microarray; adrenal gland phenotypic analysis Annals of the New York Academy of Sciences Medium 12438089
2010 A multi-hnRNP complex (containing hnRNP A1, A2/B1, and K) binds the steroid nuclear hormone receptor element cluster at the ANXA7 promoter (-1086/-890) specifically in androgen-resistant prostate cancer cells (PC3), but not in normal prostate cells (PrEC), leading to aberrant ANXA7 transcription and alternative splicing; hnRNPA2/B1 antibody interference validated this regulation. Deletion mapping/promoter activity assays; Genomatix analysis; gel-shift (EMSA); MALDI-TOF mass spectrometry identification of hnRNP proteins; antibody interference assay; Ingenuity Pathway Analysis Oncogene Medium 20190808
2012 BART binds directly to ANX7 and the BART-ANX7 complex reduces PKCα activity; knockdown of either BART or ANX7 increases PKCα activity and enhances invasiveness of pancreatic cancer cells, which is abrogated by PKCα-specific inhibitors. Co-immunoprecipitation (BART-ANX7 interaction); knockdown of BART and ANX7; PKCα activity assay; invasion assay; PKCα inhibitor treatment PloS one Medium 22532868
2012 In Anx7(+/-) beta-cells, the muscarinic agonist carbachol and ryanodine receptor agonists (caffeine, 4-chloro-m-cresol) have more potent depolarizing effects and augment glucose-induced insulin secretion; however, ryanodine receptor-mediated Ca2+ mobilization itself is not affected, indicating that the Anx7(+/-) mutation alters downstream signaling pathways associated with IP3 receptors and ryanodine receptors, not the Ca2+ stores directly. Anx7(+/-) knockout mouse beta-cells; electrophysiology; intracellular Ca2+ measurements; insulin secretion assay; pharmacological agonists (carbachol, caffeine, 4-chloro-m-cresol) Cellular physiology and biochemistry Medium 22613970
2017 Activation of ANXA7 GTPase by small molecule SEC suppresses prostate cancer metastasis by promoting AMPK phosphorylation, leading to decreased mTORC1 activity, suppressed STAT3 nuclear translocation, and downregulation of pro-metastatic genes (CCL2, APLN, IL6ST); RKIP interacts with ANXA7 and impairs SEC-induced GTPase activation and downstream signaling. Small molecule (SEC) GTPase activation; AMPK/mTORC1/STAT3 pathway analysis by Western blot; RKIP-ANXA7 interaction; in vivo orthotopic prostate cancer metastasis model Cancer letters Medium 29247827
2016 Small molecule ABO directly targets ANXA7 and inhibits its GTPase activity; inhibition of ANXA7 GTPase causes increased TGFB2-OT1 expression, which elevates LARP1, leading to enhanced HMBOX1 translation in vascular endothelial cells; ABO fails to increase HMBOX1 in ANXA7-deficient HUVECs, confirming ANXA7 dependency. Small molecule (ABO) GTPase inhibition; ANXA7 knockdown; HMBOX1 protein quantification; TGFB2-OT1/LARP1 expression analysis; in vivo apoE-/- mouse model The international journal of biochemistry & cell biology Medium 27506770
2019 Inhibition of ANXA7 GTPase activity by ABO causes ANXA7 to translocate into the nucleus where it interacts with XRN2 (5'→3' exoribonuclease); decreased XRN2 phosphorylation promotes read-through transcription of MROH7-TTC4 lncRNA, which is then processed by TIA1 into MROH7 and TTC4 to inhibit vascular endothelial cell apoptosis. GTPase inhibitor (ABO); lncRNA microarray; Co-immunoprecipitation (ANXA7-XRN2); nuclear translocation imaging; TIA1 binding assay The FEBS journal Medium 31408583
2019 ANXA7 knockdown inhibits JAK1/STAT3 pathway activation in trophoblast HTR-8/SVneo cells, reduces BCL2 levels, promotes apoptosis, and inhibits proliferation; ANXA7 overexpression has the opposite effect, establishing ANXA7/JAK1/STAT3 as a regulatory pathway in trophoblast survival. siRNA knockdown and overexpression in HTR-8/SVneo cells; Western blot; flow cytometry (apoptosis); CCK-8 proliferation assay American journal of reproductive immunology Medium 31446642
2020 ANXA7 translocates to impaired mitochondria upon CCCP-induced mitochondrial damage and plays a pivotal role in Parkin-dependent mitophagy by interacting with BASP1. Data-independent acquisition quantitative mitochondrial proteomics; mitochondrial fractionation/translocation assay; Co-immunoprecipitation (ANXA7-BASP1); CCCP treatment Journal of proteome research Medium 31975592
2020 ANXA7 overexpression promotes proliferation, cell cycle progression, and cell adhesion-mediated drug resistance in multiple myeloma cells through upregulation of CDC5L; co-immunoprecipitation confirmed ANXA7 binds CDC5L, and CDC5L knockdown reverses ANXA7 overexpression effects. ANXA7 overexpression and knockdown in U266/RPMI8226 cells; co-immunoprecipitation (ANXA7-CDC5L); proliferation, cell cycle, and apoptosis assays; BMSC co-culture drug resistance model Aging Medium 32526706
2021 LEPR interacts with ANXA7 (confirmed by co-immunoprecipitation) and regulates ERK1/2 and JAK2/STAT3 signaling via ANXA7 in hepatocellular carcinoma lymphatic metastatic cells. Co-immunoprecipitation (LEPR-ANXA7); western blot for ERK1/2 and JAK2/STAT3; LEPR knockdown/overexpression functional assays Cancer cell international Low 33397392
2023 ANXA7 interacts with LAMP5 (lysosomal-associated membrane protein 5) in neurons; the Asp411 mutation of ANXA7 markedly impairs the ANXA7-LAMP5 interaction. Activated ANXA7 GTPase promotes autophagy via the mTOR/TFEB pathway, inhibits neuronal apoptosis after OGD/R, and stabilizes LAMP5 protein expression; LAMP5 overexpression rescues defects caused by ANXA7 downregulation. Co-immunoprecipitation (ANXA7-LAMP5); site-directed mutagenesis (Asp411); GTPase activation assay; ANXA7 overexpression lentivirus; CatWalk assay (SCI mice); mTOR/TFEB pathway analysis; autophagy and apoptosis assays Cell death discovery Medium 37620352
2023 A dominant-negative triple mutant of ANXA7 (DNTM/DN-ANXA7J) in the GX(X)GT endonexin-fold repeats suppresses membrane fusion with artificial membranes, alters calcium and phospholipid binding, and in prostate cancer cells reduces IP3 receptor expression and modulates PI3K/AKT/mTOR signaling while affecting phosphatidylserine exposure, membrane permeabilization, and apoptosis. Site-directed mutagenesis (triple mutant); artificial membrane fusion assay; calcium and phospholipid binding assays; IP3R expression analysis; PI3K/AKT/mTOR pathway Western blot; cell death/apoptosis assays in prostate cancer cells International journal of molecular sciences Medium 37240163
2014 Wild-type ANXA7 in LNCaP prostate cancer cells induces G1-arrest and programmed cell death while preserving total FOXO3A expression without hyperphosphorylation (enabling FOXO3A nuclear translocation); ANXA7 tumor suppression operates through a mechanism distinct from p53, which fails to prevent SGK1-mediated FOXO3A phosphorylation and cytoplasmic retention. Transfection of wt-ANXA7 vs. p53 in LNCaP cells; cell cycle analysis; apoptosis assays; FOXO3A phosphorylation and localization analysis by Western blot; Ingenuity Pathway Analysis BioMed research international Low 24864229
2018 Wild-type ANXA7 abolishes expression of oncogenic low-molecular weight (LMW) cyclin E in hormone-resistant prostate (DU145) and breast cancer cells; a dominant-negative ANXA7 mutant (nMMM-ANXA7, lacking phosphatidylserine liposome aggregation properties) fails to abrogate LMW-cyclin E and simultaneously induces FGF8 in DU145, allowing continued cell cycle progression. Adenoviral wt-ANXA7 and dominant-negative nMMM-ANXA7 overexpression; cell cycle analysis; Western blot for LMW-cyclin E and FGF8; comparison across prostate (DU145) and breast (MDA-MB-231, -435) cancer lines Trends in cancer research Low 30369774
2024 ZBTB16 interacts with ANXA7 protein (confirmed by co-IP); ZBTB16 promotes ANXA7 expression, which subsequently inhibits Cyclin B1 expression; UHRF1 suppresses ZBTB16 by promoting ZBTB16 promoter methylation via DNMT1 recruitment, thereby reducing ANXA7 and enabling breast cancer cell proliferation. Co-immunoprecipitation (ZBTB16-ANXA7); methylation-specific PCR; ChIP assay; UHRF1/ZBTB16/ANXA7 knockdown and overexpression; cell cycle, proliferation, and apoptosis assays; in vivo xenograft Acta biochimica et biophysica Sinica Medium 39308302
2026 RNF168 promotes ubiquitination and degradation of ANXA7; loss of ANXA7 suppresses autophagy and induces NLRP3 inflammasome-mediated pyroptosis in intestinal epithelial cells, promoting Crohn's disease progression; ELK1 transcription factor upregulates RNF168 as the upstream regulator. Co-immunoprecipitation and mass spectrometry (RNF168-ANXA7 interaction); ubiquitination assay; ANXA7 knockdown/overexpression; autophagy and pyroptosis assays; IL-10 KO and RNF168flox/flox;Villin-Cre mouse models; organoids Apoptosis Medium 41518435
2025 ANXA7 acts as an adaptor protein facilitating retrograde transport of TIA1-containing ribonucleoprotein (RNP) granules by linking them to cytoplasmic dynein in axons; elevated axonal Ca2+ disrupts this linker role, causing detachment of TIA1 granules from dynein and pathological TIA1 aggregation; ANXA7 knockdown similarly impairs trafficking and causes axonopathy in vitro and in vivo. Live imaging of axonal RNP transport; ANXA7 knockdown and overexpression; Co-IP (ANXA7-TIA1-dynein); Ca2+ manipulation; in vitro and in vivo axonopathy models bioRxivpreprint Medium bio_10.1101_2025.01.16.633295
1999 ANX7/ANXA7 contains a PGQM motif in its regulatory domain; this motif is shared with HIV-1 Gag, and mutations in this motif in Gag disrupt viral replication, suggesting the motif mediates protein-protein interactions relevant to membrane fusion/secretory functions of ANXA7. Alanine scanning mutagenesis of PGQM motif in HIV-1 Gag; single- and multi-round viral replication assays; sequence homology with synexin/ANX7 Proceedings of the National Academy of Sciences of the United States of America Low 10077575
2025 ANXA7 GTPase activation promotes lipid droplet formation and mitochondria-lipid droplet interaction by interacting with PPARγ to enhance its stability and promote its nuclear translocation; this leads to Perilipin 5 upregulation, NRF2 nuclear translocation, and GPX4 expression, thereby inhibiting oxidative stress and lipid peroxidation in spinal cord injury neurons. ANXA7 GTPase activation (small molecule); Co-immunoprecipitation (ANXA7-PPARγ); PPARγ stability assay; lipid droplet and mitochondria imaging; NRF2/GPX4 expression; SCI mouse model with CatWalk assay Advanced science Medium 39996504

Source papers

Stage 0 corpus · 31 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2001 ANX7, a candidate tumor suppressor gene for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 108 11287641
1999 Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) knockout mouse. Proceedings of the National Academy of Sciences of the United States of America 108 10570150
2003 Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse. Proceedings of the National Academy of Sciences of the United States of America 69 14608035
2007 ANXA7 expression represents hormone-relevant tumor suppression in different cancers. International journal of cancer 44 17708571
2001 ANX7 as a bio-marker in prostate and breast cancer progression. Disease markers 29 11673658
2010 Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells. Oncogene 27 20190808
2011 ANXA7, PPP3CB, DNAJC9, and ZMYND17 genes at chromosome 10q22 associated with the subgroup of schizophrenia with deficits in attention and executive function. Biological psychiatry 25 21531385
2017 SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. Cancer letters 24 29247827
2019 ANXA7 regulates trophoblast proliferation and apoptosis in preeclampsia. American journal of reproductive immunology (New York, N.Y. : 1989) 21 31446642
2008 The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer. Journal of surgical oncology 20 18449914
2016 Inhibition of ANXA7 GTPase activity by a small molecule promotes HMBOX1 translation of vascular endothelial cells in vitro and in vivo. The international journal of biochemistry & cell biology 19 27506770
2012 The Anx7(+/-) knockout mutation alters electrical and secretory responses to Ca(2+)-mobilizing agents in pancreatic β-cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 19 22613970
2021 Leptin Receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7. Cancer cell international 18 33397392
2021 circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis. Cancer cell international 18 33536022
2023 Targeting ANXA7/LAMP5-mTOR axis attenuates spinal cord injury by inhibiting neuronal apoptosis via enhancing autophagy in mice. Cell death discovery 17 37620352
2013 Down-regulation of ANXA7 decreases metastatic potential of human hepatocellular carcinoma cells in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 17 23582794
2020 ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L. Aging 16 32526706
2017 ANXA7-GTPase as Tumor Suppressor: Mechanisms and Therapeutic Opportunities. Methods in molecular biology (Clifton, N.J.) 15 27807828
2012 BART inhibits pancreatic cancer cell invasion by PKCα inactivation through binding to ANX7. PloS one 15 22532868
2020 Quantitative Mitochondrial Proteomics Reveals ANXA7 as a Crucial Factor in Mitophagy. Journal of proteome research 12 31975592
2018 High ANXA7 Potentiates Eucalyptol Toxicity in Hormone-refractory Prostate Cancer. Anticancer research 11 29970503
2019 MROH7-TTC4 read-through lncRNA suppresses vascular endothelial cell apoptosis and is upregulated by inhibition of ANXA7 GTPase activity. The FEBS journal 10 31408583
2014 Diverse effects of ANXA7 and p53 on LNCaP prostate cancer cells are associated with regulation of SGK1 transcription and phosphorylation of the SGK1 target FOXO3A. BioMed research international 10 24864229
2002 Influence of the Anx7 (+/-) knockout mutation and fasting stress on the genomics of the mouse adrenal gland. Annals of the New York Academy of Sciences 8 12438089
2025 Lipid Droplets Metabolism Mediated by ANXA7-PPARγ Signaling Axis Regulates Spinal Cord Injury Repair in Mice. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 7 39996504
2018 Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin. Trends in cancer research 7 30369774
2023 A Dominant-Negative Mutant of ANXA7 Impairs Calcium Signaling and Enhances the Proliferation of Prostate Cancer Cells by Downregulating the IP3 Receptor and the PI3K/mTOR Pathway. International journal of molecular sciences 6 37240163
1999 HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication. Proceedings of the National Academy of Sciences of the United States of America 4 10077575
2024 UHRF1 knockdown induces cell cycle arrest and apoptosis in breast cancer cells through the ZBTB16/ANXA7/Cyclin B1 axis. Acta biochimica et biophysica Sinica 3 39308302
2024 Role of Annexin 7 (ANXA7) as a Tumor Suppressor and a Regulator of Drug Resistance in Thyroid Cancer. International journal of molecular sciences 1 39684934
2026 RNF168 promotes chronic colitis through ANXA7-mediated autophagy and NLRP3-driven pyroptosis. Apoptosis : an international journal on programmed cell death 0 41518435

Missed literature

Know a paper Affinage missed for ANXA7? Flag it for the maintainers and the community.

No submissions yet.